Develops therapies for neurodevelopmental and neurodegenerative disorders, focusing on innovative drug treatments.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology firm dedicated to pioneering treatments for individuals afflicted with severe neurodegenerative disorders. At the forefront of its innovative efforts is PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib. This product aims to address the complex challenges of amyotrophic lateral sclerosis (ALS), offering new hope in managing this debilitating condition. In addition to PrimeC, NeuroSense Therapeutics is actively advancing its preclinical pipeline, which includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease, aiming to broaden therapeutic options and improve outcomes for patients.
Established in 2017 and headquartered in Herzliya, Israel, NeuroSense Therapeutics embodies a commitment to transformative research and development in the field of neurology. The company leverages cutting-edge scientific insights and strategic partnerships to accelerate the progression of its promising therapies. By focusing on novel drug formulations and therapeutic approaches, NeuroSense Therapeutics aims to address unmet medical needs and make a meaningful impact on the lives of patients worldwide.
With a robust pipeline and a strong foundation in Israel's biotechnology hub, NeuroSense Therapeutics continues to expand its capabilities and explore new avenues for treating neurodegenerative diseases. By combining scientific rigor with a patient-centric approach, the company strives to deliver innovative solutions that hold the potential to transform the landscape of neurological care.